2024 年,强生肿瘤业务年度销售额首次突破 200 亿美元大关,创收 207.81 亿美元,首度超越自免(178.28 亿美元),成为强生创新药收入的第一大来源。而在 2015 年,强生肿瘤的全年收入只有 46.95 亿美元,与彼时相比,其今天的肿瘤业绩累计涨幅高达 342%,在创新药收入中的比例也由 14.9% 上升到 36.5%。十余年间,强生肿瘤业务是如何从一颗小树苗成长为了支撑公司业绩的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.